Phapros Posts Profit After Previous Year's Loss

The pharmaceutical issuer PT Phapros Tbk (PEHA) recorded a net profit of Rp 27.44 billion throughout 2025. This figure represents a 109% increase compared to the previous year, which posted a loss of Rp 290.63 billion.

Acting Director of PT Phapros, Ida Rahmi Kurniasih, stated that this achievement is the result of strengthening discipline in Sales and Operation Planning, improving the marketing team’s competence, reorganising cooperation with distributors, product portfolio strategies, and tight cost efficiencies.

“The improvement in fundamental business has driven growth in sales across all segments, thus successfully restoring the company’s sustainable profitability,” she said in a press release, quoted on Thursday, 2 April 2026.

In 2025, Phapros recorded sales of Rp 940.88 billion, up 26.34% year-on-year. Sales in the over-the-counter drugs segment rose 43.20% year-on-year. The generic branded drugs segment grew 13.95% year-on-year. Meanwhile, the ethical segment grew by up to 54.94% year-on-year.

In addition, Ida said the company managed to suppress the cost of goods sold or cost of sales by 5.41% to Rp 448.37 billion from Rp 474.03 billion in the previous year. Phapros also succeeded in reducing operating expenses by 14.64% to Rp 406.43 billion in 2025 from Rp 476.12 billion in 2024.

According to Ida, Phapros also achieved production efficiencies. This is reflected in the 5.41% decrease in cost of goods sold (COGS). The COGS to sales ratio in 2025 also fell to 47.65% compared to 63.65% in 2024. “The low COGS to sales ratio indicates that the production process is running very efficiently and gross profit margins are larger,” said Ida.

On the liabilities side, the PT Kimia Farma subsidiary succeeded in cutting liabilities from Rp 1,036.92 billion in 2024 to Rp 959.7 billion in 2025, or a 7.45% decrease. This condition drove an increase in equity in 2025 to Rp 427.47 billion, up 8.74% from the previous year’s Rp 393.12 billion.

Ida said Phapros also managed cash flow well. The company’s net cash flow from operating activities was positive at Rp 123.757 billion, with a cash balance as of 31 December 2025 at Rp 120.98 billion. This position rose 31.49% compared to the same period last year, which was Rp 92 billion.